1	The founder missense mutation of WFDC2 in Koreans leads to severe respiratory					
2	distress accompanied by bronchiectasis and rhinosinusitis					
3						
4	Jae Won Roh, ^{1,2,8} Jiyoung Oh, ^{3,8} Se Jin Kim, ^{1,2,8} Ji Won Hong, ^{1,2,8} Jiyeon Ohk, ⁴ Hyo Sup					
5	Shim, ⁵ Hyung-Ju Cho, ⁶ Ala Woo, ⁷ Song Yee Kim, ⁷ Young Ae Kang, ⁷ Hosung Jung, ⁴ Kyung					
6	Won Kim, ^{3,*} Moo Suk Park, ^{7,*} Heon Yung Gee ^{1,2,*}					
7						
8	¹ Department of Pharmacology, Graduate School of Medical Science, Brain Korea 21 Project,					
9	Yonsei University College of Medicine, Seoul 03722, Republic of Korea					
10	² Woo Choo Lee Institute for Precision Drug Development, Seoul 03722, Republic of Korea					
11	³ Department of Pediatrics, Severance Hospital, Yonsei University College of Medicine, Seoul					
12	03722, Republic of Korea					
13	⁴ Department of Anatomy, Graduate School of Medical Science, Brain Korea 21 Project,					
14	Yonsei University College of Medicine, Seoul 03722, Republic of Korea					
15	⁵ Department of Pathology, Yonsei University College of Medicine, Seoul, Korea					
16	⁶ Department of Otorhinolaryngology, The Airway Mucus Institute, Korea Mouse					
17	Phenotyping Center (KMPC), Taste Research Center, Yonsei University College of Medicine,					
18	Seoul 03722, Republic of Korea					
19	⁷ Department of Internal Medicine, Severance Hospital, Yonsei University College of					
20	Medicine, Seoul 03722, Republic of Korea					
21	⁸ These authors contributed equally					

22	*Correspondence:
----	------------------

- 23 Kyung Won Kim
- 24 Department of Pediatrics, Yonsei University College of Medicine, 50-1 Yonsei-Ro,
- 25 Seodaemun-gu, Seoul 03722, Korea; +82-2-2228-2050; email: <u>kwkim@yuhs.ac</u>
- 26

27 Moo Suk Park

- 28 Department of Internal Medicine, Yonsei University College of Medicine, 50-1 Yonsei-Ro,
- 29 Seodaemun-gu, Seoul 03722, Korea; +82-2-2228-1955; email: pms70@yuhs.ac
- 30

- 32 Department of Pharmacology, Yonsei University College of Medicine, 50-1 Yonsei-Ro,
- 33 Seodaemun-gu, Seoul 03722, Korea; +82-2-2228-8755; email: HYGEE@yuhs.ac

³¹ Heon Yung Gee

34 ABSTRACT

35 Background

36 Chronic airway diseases like cystic fibrosis (CF) and primary ciliary dyskinesia (PCD) pose

- 37 substantial clinical challenges. This study explores the p.C97W variant in WFDC2, proposed
- 38 as a new genetic origin of respiratory distress, especially among Koreans.

39 Methods

Whole-exome/genome sequencing (WES/WGS) were performed on 64 patients from 62 families presenting with severe bronchiectasis and chronic rhinosinusitis. *In vitro* analyses and protein modeling were utilized to evaluate the functional implications of the *WFDC2* variant.

44 **Results**

Pathogenic variants were found in 11.3% of families, including a novel homozygous *WFDC2* missense variant (c.291C>G, p.Cys97Trp) in five unrelated families, confirmed by Sanger sequencing. The variant, rare globally but more frequent in Koreans, caused persistent wet cough, chronic rhinosinusitis, and bronchiectasis in affected patients. Lung tissue pathology showed chronic inflammation and interstitial fibrosis. The p.C97W variant impaired WFDC2 protein folding, secretion, and function.

51 Conclusions

52 The p.C97W variant in *WFDC2* is a critical genetic factor in severe chronic airway disease 53 that shares clinical features with CF and PCD. Given its implications for diagnosis and 54 treatment, genetic testing for *WFDC2* mutations in individuals with CF or PCD-like 55 symptoms is recommended.

56 **INTRODUCTION**

57 In humans, the respiratory epithelium is critical for air transport, mucociliary clearance, and 58 immune regulation. The airway epithelium comprises various cell types, including basal, 59 ciliated, goblet, and club cells, as well as rare types like tuft cells, ionocytes, and neuroendocrine cells.¹ The mucosal surface of the respiratory tract contributes to innate 60 immune defense. Each epithelial cell type plays a distinct role in maintaining airway integrity 61 62 and the mucociliary clearance system, by producing antioxidants, protease inhibitors, antimicrobial peptides, or by secreting mucins and surfactants.^{2,3} Dysregulation of these 63 processes due to genetic or environmental factors can lead to the pathophysiology of severe 64 viral infections and chronic pulmonary disorders, including asthma,^{1,4,5} cystic fibrosis 65 (CF).^{1,6-8} and primary ciliary dyskinesia (PCD).^{1,9,10} 66

In this study, we identified a homozygous missense variant (c.291C>G, p.C97W) in *WFDC2*, a serine/threonine protease inhibitor with anti-bacterial activity, through wholeexome and genome sequencing in families affected by respiratory conditions resembling PCD. Individuals with this variant exhibited chronic inflammation, bronchiectasis, interstitial fibrosis, and infections caused by *Pseudomonas aeruginosa*. Due to its implications for diagnosis and treatment, genetic testing for WFDC2 mutations is recommended for individuals with CF or PCD-like symptoms.

74 **RESULTS**

75 Identification of the *WFDC2* variant

76 The WES or WGS analysis pipeline to identify the potential genetic causes in patients with 77 severe bronchiectasis and chronic rhinosinusitis (n = 64 from 62 families) is shown in Fig. S1. 78 Pathogenic variants were identified in 7 of the 62 families (11.3%): five with variants in 79 PCD-linked genes (six patients) and two (two patients) with CFTR variants (Fig. 1A, B). 80 Furthermore, a homozygous missense variant (c.291C>G, p.Cys97Trp) in WFDC2 was identified in five unrelated families (Fig. 1C, and Fig. S2). Sanger sequencing confirmed this 81 82 homozygous mutation in affected probands and their siblings, while the unaffected mother 83 was heterozygous (Fig. 1D). The allele frequency of this variant was 0.00001611 in the 84 global population 0.0004051 in East Asians, and 0.0018 in the Korean population, as reported 85 in the Genome Aggregation Database (gnomAD; Table S1). Haplotype analysis revealed that 86 individuals carrying the c.291C>G WFDC2 mutation shared a genomic region of 87 approximately 138.5 kb surrounding the variant (Table S2). Subsequent haplotype analysis using the LDhap Tool¹¹ using eight selected SNPs within the shared region revealed that 88 89 individuals with the c.291C>G WFDC2 mutation share a rare H4 haplotype, with a frequency 90 of 0.63% in the homozygous state (Table S2). This finding suggests this variant as a founder 91 allele.

92

93 Clinical phenotypes of individuals with the *WFDC2* variant

All six patients from five unrelated families presented with persistent wet cough and chronic rhinosinusitis (Fig. 2C). Chest CT scans revealed bronchiectasis in five patients, while one patient (P1946-21) declined the scan (Fig. 2A). Pathological examination of the original lung tissue from three female patients (P1969-21, P2678-21, and P2783-21) who underwent lung

transplantation at an average age of 33 years (range: 21–41 years; Table 1) revealed chronic
inflammation, bronchiectasis, and interstitial fibrosis (Fig. 2D). All patients had *P. aeruginosa*lung infections, and pulmonary function demonstrated a severe airflow obstruction pattern
before lung transplantation. Two siblings (P5-21 and P5-22) of three male patients recently
visited our hospital, both presenting with bronchiectasis and reduced FEV1% predicted (Fig.
2B, and Table 1).

104 The average age at the onset of respiratory symptoms was 7.8 years (range, 1 month 105 to 13 years). Initial clinical diagnoses based on respiratory symptoms included neonatal 106 pneumonia in patients P1946-21 and P1969-21; bronchiectasis in patients P2678-21, P2783-107 21, P5-21, and P5-22; and chronic rhinosinusitis in patients P5-21 and P5-22. Bronchiectasis 108 was confirmed during childhood in two-thirds of the patients, with one patient diagnosed at 109 late 0's (P2678-21) and three patients diagnosed at early 10's (P2783-21, P5-21, and P5-22). 110 The three patients who underwent lung transplants (P1969-21, P2678-21, and P2783-21) 111 have maintained stable lung structure and function for two, seven, and fourteen years, 112 respectively (Fig. 2, and Table 1).

113

114 Effect of p.C97W variant on WFDC2 function

As shown in Fig. 3A, WFDC2 contains a N-terminal signal peptide that is involved in trafficking and secretion, and two whey acidic protein (WAP) domains connected by a short loop. Each WAP domain includes eight cysteine residues that form four disulfide bonds. Structure prediction using AlphaFold2¹² showed that C97 located in the second WAP domain forms a disulfide bond with C109 (Fig. 3A). Multiple sequence alignments of human WFDC2 with its orthologs from several vertebrate species demonstrated that both C97 and C109 are highly conserved across vertebrates (Fig. 3B). Additionally, the *in silico* prediction

scores classified the C97W variant as pathogenic or disease-causing (Table S1).

123 Next, we predicted the structures of both the wild-type (WT) and p.C97W mutant WFDC2 using ColabFold¹³ and AlphaFold2.¹² The p.C97W mutant failed to form a disulfide 124 125 bond with C109, in contrast to WT (Fig. 3C). Additionally, the bulky side chain of the Trp (W) residue disrupted hydrogen bond formation near W97 in the second WAP domain (Fig. 126 3C). WFDC2 forms dimeric structures:¹⁴ therefore, we predicted the dimeric structures of WT 127 128 and p.C97W. Clustering of the structures from multiple AlphaFold2 runs showed that the 129 p.C97W structure predominantly exists in a 'trans-trans' configuration, where the second 130 WAP domain is untangled and interacts with the other subunit. In contrast, the WT WFDC2 131 dimers were more likely to exist in the 'cis' configuration (Fig. 3C, and Fig. S3).

132 Assessment of the effects of the p.C97W mutant on WFDC2 secretion in human 133 embryonic kidney (HEK293T) cells overexpressing WT or p.C97W WFDC2 revealed that 134 WT WFDC2 produced a single band of approximately 24 kDa in both the lysate and culture 135 media. In contrast, the p.C97W variant was not secreted and showed reduced expression in 136 the lysate (Fig. 3D). Immunofluorescence analysis in HEK293T cells showed colocalization 137 of both WT and p.C97W WFDC2 with the endoplasmic reticulum marker, suggesting no 138 defect in intracellular localization (Fig. S4A). Furthermore, treatment with tunicamycin, an 139 inhibitor of N-linked glycosylation, or glycosidase digestion by incubation of cell lysates 140 with glycosidases, such as PNGase F or Endo H, demonstrated that both WT and p.C97W 141 were glycosylated (Fig. S4B, C), as indicated by the shift in band molecular weight with 142 no difference between the WT and mutant (Fig. S4B, C). This finding indicated that WFDC2 was glycosylated, as previously described.¹⁴ In summary, these findings indicated 143 144 that the p.C97W mutation disrupts WFDC2 protein folding and secretion, impairing its 145 function.

146 **DISCUSSION**

147 In this study, we identified a novel WFDC2 mutation (c.291C>G; p.C97W) as the causative 148 factor in severe lung disease. This autosomal recessive variant leads to chronic inflammation, 149 bronchiectasis, interstitial fibrosis, and severe airflow obstruction, often necessitating lung 150 transplantation. Population data from gnomAD and KRGDB indicate that this allele has a 151 relatively high frequency in East Asian populations, particularly in the Korean population. 152 Based on these data, approximately three out of one million individuals are homozygous for 153 this mutation, suggesting that around 150 individuals in South Korea could be affected. In 154 contrast, the previously reported c.145T>C; p.C49R variant, identified as a European founder 155 allele, is extremely rare in East Asian populations, including Koreans. However, it has a 156 higher frequency in the European population with an allele frequency of 0.0001814, 157 equivalent to three individuals per ten million and approximately 2,239 patients in Europe. 158 Additionally, 22 loss-of-function (LoF) alleles in WFDC2 have been reported in gnomAD, 159 with a combined homozygous frequency of approximately 0.000000003178.

160 Respiratory phenotypes of WFDC2 deficiency identified in our study and another study¹⁵ present with clinical features that closely resemble CF and PCD, with symptoms 161 162 including bronchiectasis, chronic rhinosinusitis, and recurrent respiratory infections. Like CF, 163 patients with WFDC2 mutations develop bronchiectasis across all lung lobes and are prone to 164 chronic P. aeruginosa infections, indicating a more severe and diffuse impact on lung 165 structure in WFDC2 deficiency and CF compared to PCD. Furthermore, nasal and sinus 166 abnormalities, including chronic rhinosinusitis and nasal polyps, are prevalent across all three 167 conditions. In this study, three patients with WFDC2 mutations underwent lung 168 transplantation due to respiratory failure, further highlighting the severe progression of the 169 disease.

170 The WFDC2 c.291C>G; p.C97W variant shares molecular similarities with the previously described c.145T>C; p.C49R variant.¹⁵ Both are autosomal recessive missense 171 172 mutations in cysteine residues within the WAP domain, a critical region for disulfide bond 173 formation, and lead to LoF by disrupting the WAP domain. The key difference between the 174 two variants is that the p.C49R variant affects the first WAP domain, while the p.C97W 175 variant affects the second. Additionally, unlike the p.C49R variant, which is associated with glycosylation defects,¹⁵ our data did not reveal glycosylation differences for the p.C97W 176 177 variant, nor did it alter intracellular localization compared to the WT protein. Structural modeling using AlphaFold2,¹² aligns well with the disruption of WAP domain integrity due to 178 179 the loss of disulfide bonds, suggesting that improper dimer formation might explain the 180 differences in the effects of the p.C97W variant. Despite these structural differences, both 181 variants exhibit similar defects in protein secretion, suggesting comparable pathological 182 consequences in humans.

In conclusion, we identified the p.C97W *WFDC2* variant as a novel cause of severe chronic airway disease, which is physiologically distinct but clinically similar to CF and PCD. Our study revealed the prevalence of the *WFDC2* p.C97W variant in the Korean population, suggesting genetic testing for this gene could be beneficial in patients who have respiratory phenotypes resembling PCD or CF.

188 **METHODS**

189 Study design

190 This study was approved by the Institutional Review Board of Severance Hospital, Yonsei 191 University Health System (IRB #4-2013-0770 and #4-2024-0647). Written informed consent 192 was obtained from the patients for their participation in this study and the publication of their 193 clinical data. Sixty-four patients with severe bronchiectasis and chronic rhinosinusitis from 194 62 unrelated families were enrolled from both the PCD-like severe bronchiectasis and chronic 195 rhinosinusitis and lung transplantation cohorts at a single tertiary medical center in South 196 Korea. These patients met the European Respiratory Society guidelines for the clinical 197 diagnosis of PCD,¹⁶ which include symptoms such as persistent wet cough, chronic 198 rhinosinusitis, or bronchiectasis. Whole-exome sequencing (WES) or whole-genome 199 sequencing (WGS) was performed to identify potential genetic causes. In-depth genetic 200 analyses were performed on individuals without any potential molecular causes.

201

202 Analysis of whole exome/genome sequencing data

203 Genomic DNA was extracted from blood samples of patients clinically suspected of having 204 PCD using a DNeasy Kit (Qiagen, Germany). Whole exome sequencing (WES) was 205 performed using a SureSelect V5 kit (Agilent Technologies, Santa Clara, CA, USA) and an 206 Illumina HiSeq 2500. Raw WES FASTQ files were imported into CLC Genomics Workbench 207 version 9.5.3 for data analysis. Sequenced reads were mapped to the human reference 208 genome, GRCh37/hg19. Variants were detected using the Basic Variant Caller of the CLC 209 Genomics Workbench, with a minimum coverage of 5, a count of 2, and a frequency of 20%. 210 Low-coverage whole genome sequencing (WGS) was performed using a PCR-free DNBSEQ 211 platform (BGI, Beijing, China). Following GATK best practice guidelines, the reads were 10

212 aligned to the human reference genome GRCh37/hg19 using the Burrows-Wheeler Aligner 213 (BWA-MEM). Duplicates were marked, reads were sorted, and the mapping quality was 214 recalibrated using PICARD-MarkDuplicates and GATK-BOSR. Variant calling of single 215 nucleotide variants (SNVs) and small insertions and deletions (indels) was performed using 216 GATK-HaplotypeCaller, and low-quality variants with a depth of coverage (DP) < 5 and 217 genotype quality (GQ) < 20 were filtered out. Copy Number Variation (CNV) analysis was 218 performed using EXCAVATOR version 2.2 and ExomeDepth (version 1.1.10) with default 219 WES settings for the data. For WGS data. **CNV**nator 220 (v0.3.2,https://github.com/abyzovlab/CNVnator) and GATK-SV 221 (https://github.com/broadinstitute/gatk-sv) were used to detect CNV. Mitochondrial variants 222 and transposable element insertion calling were performed using Mutect2 and xTea (v0.1.9; 223 https://github.com/parklab/xTea).

224 SNVs and small indels were annotated using Variant Annotation tools in the CLC 225 Workbench or ANNOVAR software. SNVs and small indels were first filtered based on 226 minor allele frequency (MAF), applying a threshold of MAF < 1% according to the Single-227 Nucleotide Polymorphisms Database (dbSNP), Genome Aggregation Database (gnomAD), 228 and Korean Reference Genome Database (KRGDB); variants that were nonsynonymous or 229 located in splice sites were selected. To evaluate pathogenicity and prioritize the candidate 230 causing variants, in silico prediction algorithms, such as MutationTaster, Sorting Tolerant 231 from Intolerant (SIFT), Combined Annotation Dependent Depletion (CADD), Polymorphism 232 Phenotyping v2 (PP2) scores, and public databases including Online Mendelian Inheritance 233 in Man (OMIM) and ClinVar, were used. Interpretation of the variants was performed 234 according to the American College of Medical Genetics and Genomics (ACMG) guidelines. 235 To identify splice site variants, SpliceAI was run on the variants using Ensembl's Variant 11

Effect Predictor (VEP) tool and filtered using a threshold MAF of 1% and delta score threshold of 0.1. Variants were annotated based on their presence in human candidate cisregulatory elements, as identified using the SCREEN database from the Encyclopedia of DNA Elements (ENCODE) project. Confirmation of the detected variants was performed manually using the Integrative Genomics Viewer (IGV) and through segregation analysis using Sanger sequencing.

242

243 Structural prediction and clustering

AlphaFold2¹² and ColabFold¹³ were used to construct the *de novo* monomer and dimer 244 WFDC2 structures, respectively. The AlphaFold2-multimer-V2 algorithm was applied 245 246 without using a template or minimization, using three recycle number parameters in 247 ColabFold. The full-length WT or p.C97W human WFDC2 sequence was used as input. To 248 generate different structural conformations, multiple runs were conducted using different seed 249 values in ColabFold software. A total of 100 different structures were generated for the WT 250 monomer. C97W, homodimer WT, and p. C97W. The monomer and dimer structures were 251 then structurally aligned to perform principal component analysis (PCA) using the bio3d package¹⁷ in R. The K-means algorithm was implemented to cluster the structures. The 252 optimal number of clusters suggested by R. ChimeraX¹⁸ was used to visualize protein 253 254 structures.

255

256 Cell culture, plasmids, and transfection

Human embryonic kidney (HEK) 293T cells (#CRL-3216, American Type Culture Collection,
 Manassas, VA, USA) were cultured in Dulbecco's modified Eagle's medium (DMEM)
 supplemented with 10% fetal bovine serum and penicillin (50 IU/mL)/streptomycin

260 (50 μ g/mL; Invitrogen, Waltham, MA, USA). The cells were incubated in a 5% CO₂ 261 environment at 37°C.

262 Plasmids encoding human *WFDC2* (NM 006103.4) and mouse Wfdc2 263 (NM_026323.2, isoform 1 and NM_001374655.1, isoform 2) were purchased from OriGene 264 (Rockville, MD, USA). The coding sequences were amplified by PCR and subcloned into the 265 pcDNA3.4 vector using XbaI and AgeI sites. During PCR, 10xHIS tags were inserted directly 266 into the 3' end in front of the stop codon. Human and mouse WFDC2 mutants were 267 introduced using the QuikChange mutagenesis method (Agilent Technologies). The pEYFP-268 ER plasmid was purchased from NovoPro Biosciences (San Diego, CA, USA).

HEK293T cells were seeded in 6-well plates the day before transfection. Plasmids were transfected using a PEI-MAX transfection reagent (Polysciences, Warrington, PA, USA) according to the manufacturer's protocol. A total of 0.5 μ g of the desired plasmid and 2 μ L of PEI-MAX was used for transfection. Cells were used for experiments 24–48 h posttransfection.

274

275 **Immunoblotting**

Forty-eight hours after transfection, HEK293T cells were washed twice with phosphatebuffered saline (PBS) and harvested in a lysis buffer containing 150 mM NaCl, 50 mM Tris-HCl (pH 7.4), 1 mM EDTA, 1% Triton X-100, and 1x protease inhibitor cocktail (#04693116001, Sigma-Aldrich, St. Louis, MA, USA). The cells were then briefly sonicated to break the cell membrane and homogenize the sample. Bradford assay was performed to measure the protein concentration at an absorbance of 595 nm. Cell lysates (40–60 μg) were used for analysis.

283

The samples were incubated in 2x sodium dodecyl sulfate (SDS) sample buffer

containing dithiothreitol (DTT, 0.02 g/mL) for 30 min at room temperature and subsequently separated using SDS-polyacrylamide gel electrophoresis (PAGE). The separated proteins were transferred onto a nitrocellulose membrane (GE Healthcare, Chicago, IL, USA), which was blotted using suitable primary antibodies and horseradish peroxidase-conjugated secondary antibodies in 5% skimmed milk. Protein bands were visualized using the SuperSignal West Pico kit (Thermo Fisher Scientific) and a blue film (Afga, Belgium). The density of each protein band was quantified using the ImageJ software (https://imagej.net/ij/).

To detect secreted WFDC2 proteins, transfected cells were incubated in a serum-free medium for 24 h. Culture media were collected and concentrated using Amicon Ultra-4 filters (Millipore, Burlington, MA, USA). The concentrated media was directly heated with 2x SDS sample buffer with DTT and subjected to SDS-PAGE.

The following primary and secondary antibodies were used: anti-HIS (#2365, Cell Signaling Technologies, Danvers, MA, USA; 1:1000 dilution), anti-ALDOA (#sc-390733, Santa Cruz Biotechnology, Santa Cruz, TX, USA; 1:000 dilution), HRP Anti-beta Actin antibody (#ab20272, Abcam, Cambridge, UK; 1:2000 dilution), goat anti-rabbit IgG polyclonal antibody (HRP conjugate) (#ADI-SAB-300-J, Farmingdale, Enzo Life Sciences, NY, USA), and goat anti-mouse IgG F(ab')2 polyclonal antibody (HRP conjugate) (#ADI-SAB-100-J; Enzo Life Sciences; 1:1000 dilution).

302

303 Immunocytochemistry

Transfected HEK293T cells were cultured on an 18 mm round coverslip. Cells were washed twice with PBS, fixed with 4% paraformaldehyde for 10 min, again washed twice with PBS, and permeabilized with 0.15% Triton X-100 in PBS for 10 min. The cells were washed twice with PBS and incubated with a blocking buffer consisting of 5% donkey serum for 1 h at 14

308 room temperature. After blocking, the cells were incubated with the appropriate primary 309 antibodies for 1 h at room temperature and washed three times with PBS. Subsequently, the 310 cells were stained with secondary antibodies conjugated to a fluorescent marker for 1 h at 311 room temperature and washed thrice with PBS. The samples were mounted onto glass slides 312 using a mounting medium (Agilent Dako, CA, USA), and images were captured using a 313 confocal microscope (LSM 700, Carl Zeiss, Germany) equipped with a 40× objective lens.

The following primary and secondary antibodies were used: anti-HIS (#2365, Cell Signaling Technologies; 1:200 dilution), Alexa Fluor 594 donkey anti-rabbit (#A21207, Invitrogen; 1:400 dilution), Alexa Fluor 647 Phalloidin (#A22287, Invitrogen; 1:400 dilution).

317

318 **Deglycosylation assay**

319 Two methods were used to determine the glycosylation state of WFDC2. After transfection, 320 cells were treated with 2 µM tunicamycin (Sigma-Aldrich) for 20 h. A higher dose or longer 321 incubation time with tunicamycin caused excessive cell death, preventing further analysis. 322 The cells were harvested and subjected to SDS-PAGE, followed by immunoblotting. 323 Transfected cells were denatured in 2x SDS sample buffer containing DTT. Denatured 324 samples were incubated with PNGase F or Endo H (New England Biolabs, Ipswich, MA, 325 USA) according to the manufacturer's protocol. Deglycosylated samples were analyzed using 326 SDS-PAGE and immunoblotting. The shift in protein size was analyzed using both methods.

327 FUNDING AND SUPPORT

- 328 This work was supported by the National Research Foundation (NRF) grants funded by the
- 329 Korean government (2018R1A5A2025079 and RS-2023-00261905 to H.Y.G. and the Korea
- 330 Mouse Phenotyping Project RS-2024-00400118 to H.Y.G.). This work was supported by the
- 331 National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT)
- 332 (No. 2022R1A2C1010462 to K.W.K.).

333

334 COMPETING INTERESTS

- 335 The authors declared that no conflicts of interest.
- 336

337 ACKNOWLEDGEMENTS

- 338 We thank the families that participated in this study. We also thank the Yonsei Advanced
- 339 Imaging Center and Carl Zeiss Microscope.

340 **REFERENCES**

- 3411.Davis JD, Wypych TP. Cellular and functional heterogeneity of the airway epithelium. Mucosal342Immunol 2021;14(5):978-990. DOI: 10.1038/s41385-020-00370-7.
- 343 2. Hiemstra PS, McCray PB, Jr., Bals R. The innate immune function of airway epithelial cells in
 344 inflammatory lung disease. Eur Respir J 2015;45(4):1150-62. DOI:
 345 10.1183/09031936.00141514.
- Lee S-N, Yoon J-H. The Role of Proprotein Convertases in Upper Airway Remodeling.
 Molecules and Cells 2022;45(6):353-361. DOI: https://doi.org/10.14348/molcells.2022.0019.
- Jevnikar Z, Ostling J, Ax E, et al. Epithelial IL-6 trans-signaling defines a new asthma
 phenotype with increased airway inflammation. J Allergy Clin Immunol 2019;143(2):577-590.
 DOI: 10.1016/j.jaci.2018.05.026.
- 3515.Vieira Braga FA, Kar G, Berg M, et al. A cellular census of human lungs identifies novel cell352states in health and in asthma. Nat Med 2019;25(7):1153-1163. DOI: 10.1038/s41591-019-3530468-5.
- 3546.De Rose V, Molloy K, Gohy S, Pilette C, Greene CM. Airway Epithelium Dysfunction in Cystic355Fibrosis and COPD. Mediators Inflamm 2018;2018:1309746. DOI: 10.1155/2018/1309746.
- 3567.Zoso A, Sofoluwe A, Bacchetta M, Chanson M. Transcriptomic profile of cystic fibrosis airway357epithelial cells undergoing repair. Sci Data 2019;6(1):240. DOI: 10.1038/s41597-019-0256-6.
- 3588.Whitsett JA. Airway Epithelial Differentiation and Mucociliary Clearance. Ann Am Thorac Soc3592018;15(Suppl 3):S143-S148. DOI: 10.1513/AnnalsATS.201802-128AW.
- Leigh MW, Horani A, Kinghorn B, O'Connor MG, Zariwala MA, Knowles MR. Primary Ciliary
 Dyskinesia (PCD): A genetic disorder of motile cilia. Transl Sci Rare Dis 2019;4(1-2):51-75.
 DOI: 10.3233/TRD-190036.
- 36310.Bustamante-Marin XM, Ostrowski LE. Cilia and Mucociliary Clearance. Cold Spring Harb364Perspect Biol 2017;9(4). DOI: 10.1101/cshperspect.a028241.
- Machiela MJ, Chanock SJ. LDlink: a web-based application for exploring population-specific
 haplotype structure and linking correlated alleles of possible functional variants.
 Bioinformatics 2015;31(21):3555-7. DOI: 10.1093/bioinformatics/btv402.
- 36812.Jumper J, Evans R, Pritzel A, et al. Highly accurate protein structure prediction with369AlphaFold. Nature 2021;596(7873):583-589. DOI: 10.1038/s41586-021-03819-2.
- 370
 13. Mirdita M, Schutze K, Moriwaki Y, Heo L, Ovchinnikov S, Steinegger M. ColabFold: making
 371 protein folding accessible to all. Nat Methods 2022;19(6):679-682. DOI: 10.1038/s41592-022372 01488-1.
- 37314.Bingle L, Armes H, Williams D, et al. Expression and function of murine WFDC2 in the374respiratory tract. bioRxiv 2020;2020.05.05.079293. DOI: 10.1101/2020.05.05.079293.
- 375 15. Dougherty GW, Ostrowski LE, Nöthe-Menchen T, et al. Recessively Inherited Deficiency of

376 Secreted WFDC2 (HE4) Causes Nasal Polyposis and Bronchiectasis. Am J Respir Crit Care 377 Med 2024;210(1):63-76. (In eng). DOI: 10.1164/rccm.202308-1370OC. 378 16. Lucas JS, Barbato A, Collins SA, et al. European Respiratory Society guidelines for the 379 Respir diagnosis of primary ciliary dyskinesia. Eur J 2017;49(1) DOI: 380 10.1183/13993003.01090-2016. 381 17. Grant BJ, Rodrigues AP, ElSawy KM, McCammon JA, Caves LS. Bio3d: an R package for 382 the comparative analysis of protein structures. Bioinformatics 2006;22(21):2695-6. DOI: 383 10.1093/bioinformatics/btl461. 384 18. Pettersen EF, Goddard TD, Huang CC, et al. UCSF ChimeraX: Structure visualization for 385 researchers, educators, and developers. Protein Sci 2021;30(1):70-82. DOI: 386 10.1002/pro.3943. 387 19. Waterhouse AM, Procter JB, Martin DM, Clamp M, Barton GJ. Jalview Version 2--a multiple 388 sequence alignment editor and analysis workbench. Bioinformatics 2009;25(9):1189-91. DOI: 389 10.1093/bioinformatics/btp033.

FIGURE LEGENDS



392

Fig. 1. Identification of a homozygous variant in *WFDC2* in families with severe
bronchiectasis and chronic rhinosinusitis.

(A, B) Summary and result of WES/WGS analysis to elucidate the causal variants in patients
with severe bronchiectasis and chronic rhinosinusitis. Five families had a homozygous
variant in *WFDC2*, which was the c.291C>G substitution resulting in the amino acid change
p.Cys97Trp. (C) Pedigree of five families with the c.291C>G *WFDC2* variant. The probands
are indicated using arrows. (D) Sanger sequencing result of c.291C>G *WFDC2* variant
representing individuals from three families. The altered amino acid is written in red. WES,
Whole exome sequencing; WGS, whole genome sequencing.







Fig. 2. Clinical manifestation of individuals with bi-allelic WFDC2 variant.

404 (A) Radiologic findings of patients with progressive destructive lung diseases requiring lung
 405 transplantation. Left panels display extensive cystic/cylindrical bronchiectasis with bronchial
 406 wall thickening, fibrosis, and air trappings. Additionally, peribronchial and centrilobular 20

407	nodules are present, along with consolidations and bronchial mucoid stagnations (P1969-22),
408	parenchymal destruction in the right upper lobe (P2678-22), and volume loss in both upper
409	lobes (P2678-22). Right panels demonstrate much improved radiologic findings after lung
410	transplantation, with no evidence of bronchiectasis, bronchial wall thickening, fibrosis, or air
411	trappings. (B) P5-21 and P5-22 showed diffuse bronchiectasis with mucoid impactions and
412	centrilobular nodules in both lungs. (C) Nasal endoscopic images showing polyposis and
413	thick mucoid discharge. (D) Lung histology H&E staining images acquired during
414	transplantation. Pathologic signs showed bronchiectasis with peribronchial inflammation and
415	fibrosis (P1969-21) and bronchiectasis and brochiolectasis with peribronchial inflammation
416	and fibrosis (P2678-21). In (D), the scale bars are 50 µm. H&E, hematoxylin and eosin.





419 (A) Overall structure of the WFDC2 protein. Two WAP domains and the disulfide bond-420 forming cysteines are shown. C97 forms a disulfide bond with C109. (B) Multiple sequence 421 alignment of human WFDC2 against its orthologs from five different vertebrate species was performed using Jalview.¹⁹ The mutated amino acid residue (C97) and the disulfide bond-422 423 forming cysteine residue with C97 (C109) are indicated. (C) Monomer and homo-dimer structure prediction of WFDC2 WT and p.C97W mutant by AlphaFold2.^{12,13} (D) Western blot 424 analysis of WT and p.C97W mutant WFDC2 proteins in both the lysates and secreted media 425 426 of HEK293T cells overexpressing the proteins. In (D), data are presented in mean \pm standard 427 error of the mean. In (D), a two-way Student's t-test was used to calculate the p-value, and a 428 p-value < 0.05 was considered significant. *, p < 0.05; ****, p < 0.0001.

Patient	P1946-21	P1969-21	P2678-21	P2783-21	P5-21	P5-22
Age at confirmation of <i>WFDC2</i> mutation, years	31-35	36-40	46-50	31-35	21-25	21-25
Sex	Male	Female	Female	Female	Male	Male
Bronchiectasis	N/A	Yes	Yes	Yes	Yes	Yes
Psuedomonas aeruginosa infection	N/A	Yes	Yes	Yes	N/A	N/A
Chronic rhinosinusitis	Yes	Yes	Yes	Yes	Yes	Yes
Nasal polyposis	No	No	No	Yes	Yes	Yes
Age at transferred, years	26-30	31-35	36-40	16-20	21-25	21-25
Lung Transplantation (age, years)	No	Yes (36-40)	Yes (41-45)	Yes (21-25)	No	No
Medical history of siblings	Deceased due to pneumonia	No	Reduced lung function	No	Sibling of P5- 22	Sibling of P5- 21
Pulmonary function [*]						
FEV ₁ (% pred)	N/A	29	21	22	85	71
FEV_1 (L)	N/A	0.86	0.56	0.69	3.55	3.14
FEV ₁ /FVC (%)	N/A	44	49	44	81	81
DLCO	37					

Table 1. Clinical characteristics of the patients

429 N/A, data not available

^{*} Pulmonary function tests were performed just before lung transplantation for P1969-21, P2678-21, and P2783-21, and most recently for P5-

431 1 and P5-2.